News & Videos - ABBVIE INC.

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire NORTH CHICAGO, Ill., May 31, 2024 The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC) 1,2 In both trials, the primary endpoint of clinical remission (per Adapted Mayo...

AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform PR Newswire NORTH CHICAGO, Ill., May 28, 2024 New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC),...

AbbVie Completes Acquisition of Landos Biopharma PR Newswire NORTH CHICAGO, Ill., May 23, 2024 - Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is...

BaseLaunch announces a new partnership with AbbVie PR Newswire BASEL, Switzerland, May 22, 2024 Further strengthens BaseLaunch's global pharma industry partnerships 24 early-stage biotech ventures have now been supported by BaseLaunch Portfolio companies have raised over US$ 600 million in equity capital. BASEL, Switzerland , May 22, 2024 /PRNewswire/ -- BaseLaunch, the Basel -based biotech venture incubator, today announces that AbbVie has become its newest partner. Through this strategic...

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® PR Newswire NORTH CHICAGO, Ill., May 17, 2024 - AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) - Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI ® ) versus ustekinumab (STELARA ® ) in...

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders PR Newswire NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 - Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK , May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh...

AbbVie to Present at the Bank of America Securities Healthcare Conference PR Newswire NORTH CHICAGO, Ill., May 6, 2024 NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and...

AbbVie Reports First-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., April 26, 2024 Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31 , a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $12.310 Billion , an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational...

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study PR Newswire NORTH CHICAGO, Ill., April 25, 2024 Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 16 1 LEVEL UP, a Phase 3b /4 head-to-head study, compared upadacitinib to...

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands PR Newswire IRVINE, Calif., April 23, 2024 Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX ® Cosmetic, the JUVÉDERM ® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards Program IRVINE, Calif. , April 23, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to...

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis PR Newswire NORTH CHICAGO, Ill., April 18, 2024 − Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ ® ; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid...

Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie PR Newswire MILWAUKEE, April 16, 2024 MILWAUKEE , April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie . Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at...

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine PR Newswire NORTH CHICAGO, Ill., April 12, 2024 - Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48...

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne PR Newswire IRVINE, Calif., April 9, 2024 From the makers of BOTOX ® Cosmetic, two new SkinMedica ® acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica ® by the makers of BOTOX ® Cosmetic. The SkinMedica ® Acne...

AbbVie to Host First-Quarter 2024 Earnings Conference Call PR Newswire NORTH CHICAGO, Ill., April. 4, 2024 NORTH CHICAGO, Ill. , April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the...

Shareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVie PR Newswire MILWAUKEE, March 25, 2024 MILWAUKEE , March 25, 2024 /PRNewswire/ -- Ademi LLP is investigating Landos (NASDAQ: LABP) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie . Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995. There...

Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics PR Newswire IRVINE, Calif., March 25, 2024 Allergan Aesthetics is raising the conversation on patient safety and ethical standards As part of its established Aesthetics-Ethics program, this year's Anti-Age Medicine World Congress (AMW C) launches Moving the Needle on Ethics Book Thought-provoking articles and interviews with leading medical practitioners from around the world...

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases PR Newswire NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK , March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under...

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients PR Newswire NORTH CHICAGO, Ill., March 22, 2024 - The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC) - Data show that ELAHERE treatment resulted in an overall survival benefit and...

ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024 PR Newswire IRVINE, Calif., March 21, 2024 -- Two expert-led Allergan Medical Institute (AMI) symposia will explore a personalized approach to aesthetics, featuring live injection sessions with Dr Mauricio De Maio , Dr Mansi Mukherjee and Dr Steven Liew -- -- World class experts to convene on socially transformative aesthetic medicine at Science of Aging...